Go or no go? Karyopharm awaits a verdict on selinexor
A delayed decision on Karyopharm’s selinexor is the pick of the bunch for July.
Upcoming events – Pivotal data readouts for Ardelyx and Rhythm will set the tone for next year
Both Ardelyx and Rhythm Pharmaceuticals are looking for phase III clinical wins to kick off filing discussions for pipeline leads.
Upcoming events – Novartis and Miragen hope for heartening data
Upcoming data could help Novartis broaden the reach of its heart failure drug Entresto, while Miragen awaits a key test of its microRNA approach.
Upcoming events – Crucial data approach on zanubrutinib and filgotinib
Beigene seeks very good data in Waldenström's macroglobulinaemia, while Galapagos aims to extend filgotinib's reach.
Upcoming events – Protagonist and Pfizer target rare diseases
Protagonist Therapeutics and Pfizer will soon get an idea of their respective chances in beta-thalassaemia and Duchenne muscular dystrophy.
Upcoming events – Anaptysbio and Retrophin await big readouts
Anaptysbio’s etokimab needs to beat Dupixent, while Retrophin takes aims at an underserved rare disease.
Go or no go? Merck, Regeneron and Alexion await US expansion
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
Upcoming events – key tests approach for Biogen and Kalvista
Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.
Upcoming events – Phase III data for Chiasma and Novartis
Chiasma hopes to be able to file its oral acromegaly therapy by year-end, and Novartis wants to shore up its MS franchise.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.